How is tesamorelin acetate identity documented?

What does the name tesamorelin acetate require in a laboratory identity header?

A laboratory identity header for tesamorelin acetate should record the analyte name as it will appear on chromatograms, spectra and the certificate, together with the salt designation and a statement that the name remains a literature designation until lot data confirm it. Cited papers describe tesamorelin as a growth hormone-releasing factor analogue and as a synthetic human growth hormone-releasing factor (PMID:19243281; PMID:17086939). A discovery note uses the unqualified name tesamorelin (PMID:21283099). Two further bibliographic records carry the short name and are cited only for spelling consistency (PMID:22298602; PMID:22050344). Those statements show why the header must not collapse the peptide name, the growth hormone-releasing factor class and the acetate designation into one unchecked synonym.

The header should separate three strings. The first is the parent name used in the cited literature. The second is the salt designation, here acetate, which is a compositional claim and not a synonym for sequence. The third is any internal material code or vial text supplied with the lot. If those strings disagree, the disagreement is an identity finding. The header should also record the lot number, the laboratory sample identifier, the analysis date and the reviewer. A later reader should be able to see which container was tested without inferring that every similarly labelled container is the same material.

Because the supporting papers are reviews rather than method monographs, the header must not cite them as the source of a molecular formula, a monoisotopic mass or an acceptance window. A theoretical mass taken from an internal specification should be referenced as an internal document. Literature citations should remain limited to nomenclature. The header should state, in plain language, that the record characterises a named research material and that the material is not for human use. It should list only methods that were actually run. A method named but not performed should not appear as if it had produced a result. A reviewer comparing the header with the worklist should be able to match each named method to a data-file identifier, and a method without a file should be removed from the header rather than left as an implied test.

How should literature nomenclature be kept apart from lot-specific identity evidence?

A citation can support the spelling and chemical class of a name. It cannot show that a particular container holds that substance. For tesamorelin acetate, the citations establish a description as a human growth hormone-releasing factor analogue (PMID:19243281), as a synthetic human growth hormone-releasing factor (PMID:17086939), and as the short name used in a discovery summary (PMID:21283099). Two further records are bibliographic spelling anchors only (PMID:22298602; PMID:22050344). On the evidence of those bibliographic records, none supplies a chromatogram, a spectrum or a numerical limit for a batch file.

Lot-specific identity evidence comes only from measurements on the sampled container. A minimum identity block pairs at least two observations that fail for different reasons if the wrong peptide is present. Intact mass, stated with charge-state handling, addresses elemental composition within the accuracy of the instrument. A tandem mass spectrum, interpreted against a written sequence hypothesis, addresses residue order only where fragment coverage allows. Retention against a qualified reference, where one exists, addresses behaviour under a stated method. Each observation should name the instrument class, the date, the sample identifier and the comparison rule. The sentence "consistent with tesamorelin" is not a result unless that rule is written beside it.

The comparison rule should be local to the method. It may be an intact-mass difference in a stated unit, a list of required fragment ions, or a retention-time window from reference injections in the same sequence. These are documentation patterns, not limits taken from the cited reviews. If no reference material has been qualified, the report should say so. Discordant results should be kept. An out-of-window mass and an in-window retention time are not averaged into a pass. They are reported as discordant observations. The reviews should sit in a nomenclature bibliography, separate from the results table, so citation-based sentences cannot be mistaken for measurements. A cross-reference column can list the bibliography version beside the sample identifier so that a later reader can see which title strings were in force when the header was signed.

Which mass-spectrometric fields belong in a tesamorelin acetate identity block?

Mass-spectrometric identity for tesamorelin acetate is a set of fields, not a single annotated peak. The block should state the ionisation mode, the mass-analyser class, the calibration reference used that day, and whether the reported figure is a monoisotopic mass, an average mass or an m/z value at a stated charge. The cited literature establishes the name and the description as a synthetic growth hormone-releasing factor analogue (PMID:17086939; PMID:19243281). It does not establish the mass to print beside a spectrum. Any theoretical mass must come from the laboratory specification, with the sequence hypothesis written out, rather than from a review title.

The record should show how charge states were assigned and should report the states actually observed. If software combined states into a zero-charge mass, the mass range, the software version and the deconvolution settings should be named. Manual inspection of at least one raw charge state should be noted when the deconvoluted value is the figure compared with the specification. Adducts that can shift an apparent mass, including sodium or potassium adducts, should be listed as considered or excluded. The acetate designation is not itself an intact-mass result. The report should state whether the comparison mass includes or excludes counterion mass, because acetate may not remain associated under the ionisation conditions used.

Where tandem spectra are acquired, they should carry the same sample identifier as the intact-mass file. The interpretation should list fragment ions required by the sequence hypothesis and should state coverage limits. If tandem data were not acquired, the identity statement should be limited to elemental composition within the stated tolerance, not residue order. A chromatogram does not repair missing fragment coverage. The raw file name, processing method and reviewer sign-off should be cross-referenced. A mass match characterises the research material under the stated method. The material is not for human use, and the match does not alter the research-use limit recorded in the header. The comparison should also name the calibration file used that day so that a later recalculation can be checked against the same reference masses.

How should chromatographic purity be recorded without treating it as net content?

Chromatographic area percent and peptide content are different results. For a tesamorelin acetate lot, the purity statement should name the column, mobile-phase components, gradient timetable, flow rate, column temperature, detection wavelength, injection volume and sample solvent used in that sequence. The figure is method-defined. It should not be carried forward under a changed method without a bridging note. Reviews that name tesamorelin as a growth hormone-releasing factor analogue are not chromatographic monographs (PMID:19243281; PMID:22298602). They must not be cited as the origin of a purity percentage or a relative retention time.

The table should list the main peak and each integrated related peak above the reporting threshold, with retention time, relative retention time if used, area, area percent and a peak code. Area percent is a response-normalised observation at the settings used. It is not a mass fraction and it is not net peptide content. Signals excluded as solvent or counterion-related should have the exclusion rule written down. A peak labelled unknown should stay unknown until an orthogonal observation supports an assignment. Where a diode-array or mass-selective check was used, the criterion applied should sit beside the area percent. If that check was not run, the report should not imply spectral homogeneity.

System suitability should show blanks, any reference injections, and the sample injections, with identifiers matching the vial and the lot. Resolution, tailing and retention repeatability should be judged against limits in the method, not against limits inferred from review articles (PMID:17086939; PMID:21283099). A failed suitability injection invalidates the purity number that follows it. The narrative sentence should restate the number, the method identifier, the wavelength and the reporting threshold. It should also state that the chromatogram alone does not confirm sequence, counterion content or the absence of impurities with no response at the detection wavelength. Peak codes should stay stable across repeat injections of the same sequence so that a related-peak table can be compared without renaming signals. A code reused for a different retention time should be treated as a transcription error and corrected in an amendment that preserves the first table.

What must the acetate designation show in counterion and content records?

The word acetate in tesamorelin acetate is a compositional designation. It asserts a counterion claim, or at least a label claim, and it is not self-proving. Counterion identity and counterion amount should be reported with the method used, such as an ion-chromatographic determination or another named counterion assay in the method file. The growth hormone-releasing factor literature supports the peptide name (PMID:17086939; PMID:19243281; PMID:21283099). It does not report an acetate specification for a research container, and it should not be quoted as if it did.

Net peptide content is a separate line from both area percent and the counterion result. It asks how much of the weighed solid is peptide after the non-peptide contributions that were actually measured, which may include counterion and moisture, have been accounted for. If moisture is determined, the method, the sample mass and the result should appear beside the calculation. If a contribution was not measured, the statement should say that the correction was not applied. Treating area-normalised purity as net content misstates the amount of peptide associated with the container and makes later comparisons unreliable.

A coherent mass-balance note shows peptide-related chromatographic response, assigned counterion, moisture if measured, and residual unknowns, and it states whether the sum is informative or incomplete. An incomplete balance is an acceptable documented state. A balance built from assumed counterion or assumed moisture is not. If the intact-mass comparison excluded counterion, the acetate assay must not be described as confirming that mass. Certificate text, chromatogram sample name and vial text should use the same salt designation. If no counterion assay was performed, the salt name should be qualified as a label claim, not as a result. The content figure should sit beside the research-use limit, and the file should state that the material is not for human use, so that a peptide amount remains a calculated mass-balance figure.

How should data integrity and research-use limits close the batch file?

A batch file for tesamorelin acetate is complete only when each reported value can be traced to a sample, a method and a person. The chain should include the lot number, the laboratory sample identifier, the worklist name, the data-file identifier and the certificate version. Those identifiers should match across the identity block, the chromatographic table and the counterion or content section. A mismatch is a documentation failure even when the numbers look acceptable. Entries should show who generated them, when they were generated, and whether a later amendment preserved the original value.

Sign-off should be method-specific. The person confirming a mass assignment may differ from the person confirming integration. Each sign-off should state what was inspected, such as the native spectrum rather than only a processed mass, or the peak table rather than only an image. A single signature with no scope statement does not meet that expectation. Amendments after sign-off should be dated, reasoned and linked to the superseded version. The nomenclature bibliography should be versioned with the file so that a later edit cannot add a citation as if it had supported the original numbers.

The research-use statement should be operational. It should say that the file documents analytical observations on a named research material; that literature describing tesamorelin as a synthetic growth hormone-releasing factor (PMID:17086939; PMID:19243281), or listing the name in review titles (PMID:22298602; PMID:22050344; PMID:21283099), is not lot evidence; and that the material is not for human use. Wording from article titles should not be copied into the results section. Retention rules should state how long native files and the signed certificate are kept. An invalidated result should remain visible. Removing a failed chromatogram and reporting only a repeat injection destroys the audit trail. The closed file is a characterisation record and a nomenclature audit, not a commercial listing. The bibliography version, the method version and the certificate version should be readable from the same cover page. If any of those versions changes after sign-off, the cover page should show both the original identifier and the amended identifier, with the reason written in the amendment log.

Frequently asked questions

Does a published review confirm that a container is tesamorelin acetate?

No. Reviews can support the spelling and the description of tesamorelin as a synthetic growth hormone-releasing factor analogue (PMID:17086939; PMID:19243281). They do not test a container. Identity requires lot-specific measurements, a written comparison rule and a sample identifier that matches the certificate. A literature name in the header is a claim, not a pass.

Is chromatographic area percent the same as net peptide content?

No. Area percent is a response-normalised result for a stated method, wavelength and reporting threshold. Net peptide content asks how much of the weighed solid is peptide after measured non-peptide contributions, such as counterion or moisture, have been accounted for. Reporting one figure under the other name misstates the amount of peptide associated with the lot and should be treated as a documentation error.

Does the word acetate prove the counterion on the lot?

No. Acetate in the material name is a designation until a counterion assay supports it. If no assay was run, the certificate should qualify acetate as a label claim. The growth hormone-releasing factor reviews cited here do not supply an acetate specification (PMID:21283099; PMID:19243281). A mass comparison that excluded counterion mass also does not prove the salt.

Should article titles be copied into the results section?

No. Cited titles are bibliographic strings and are not lot findings (PMID:22298602; PMID:22050344). Copying title wording into a results table would present review language as if it were a measurement. Results should contain only observations from the sampled container, with method identifiers and comparison rules. Nomenclature citations belong in a separate bibliography. A title that adds a salt word, a class word or another descriptor should be transcribed into the bibliography as printed, then compared with the vial string as a separate nomenclature check.

What does an intact-mass match show, and what does it not show?

An intact-mass match, within a stated tolerance and with charge-state handling recorded, supports consistency with an elemental composition. It does not by itself confirm residue order, acetate content or chromatographic purity. Residue order requires fragment evidence against a written sequence hypothesis. Counterion content requires a separate assay. The material is not for human use, and the mass match does not change that research-use limit.

Is a chromatogram image enough to archive the purity result?

A portable-document image helps a reader see peak shape, but it is not the original record. The archive should retain the native data file, the processing method, the sequence identifiers and the reviewer scope. If a result is later questioned, those files are what show integration, suitability and sample identity. An image alone cannot support that check.

References

1. PMID:19243281 — Tesamorelin, a human growth hormone releasing factor analogue — Expert Opin Investig Drugs — 2009
2. PMID:17086939 — Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor — Curr Opin Investig Drugs — 2006
3. PMID:21283099 — Tesamorelin — Nat Rev Drug Discov — 2011
4. PMID:22298602 — Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy — Ann Pharmacother — 2012
5. PMID:22050344 — Spotlight on tesamorelin in HIV-associated lipodystrophy — BioDrugs — 2011

Research use only

This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.